Feasibility and effectiveness of second-line chemotherapy with mitomycin C in patients with advanced penile cancer
BackgroundTriple-drug cisplatin- and taxane-based chemotherapy is the standard treatment for metastatic penile squamous cell cancer (PeSCC), with a moderate response rate of 30% to 38%. Relapse after first-line chemotherapy has a poor prognosis and there is no established second-line treatment. Mito...
Main Authors: | Desiree Louise Draeger, Oliver W. Hakenberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Urology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fruro.2023.1198980/full |
Similar Items
-
Metastasis in penile corpus cavernosum from esophageal squamous carcinoma after curative resection: a case report
by: Lingmin Song, et al.
Published: (2019-02-01) -
Penile-sparing modalities in the management of low-stage penile cancer
by: Paurush Babbar, et al.
Published: (2018-01-01) -
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
by: Marco Racioppi, et al.
Published: (2018-12-01) -
Electrochemotherapy with Mitomycin C Potentiates Apoptosis Death by Inhibiting Autophagy in Squamous Carcinoma Cells
by: Maria Condello, et al.
Published: (2021-07-01) -
Curcumin improved liposomal mitomycin-induced cell toxicity in bladder cancer cell
by: Farjad Amanolahi, et al.
Published: (2018-10-01)